Jean Jeong, Brian Delaney, Katie St. Peters, Ted Ughetta, Sarah Nolan, Soo Young Hong, Steve Butler, Grant Newman
January 24, 2026
Kirkland Advises SR One on Close of Second Venture Fund at $600 Million
1 min
AI-made summary
- Kirkland & Ellis advised SR One, a transatlantic life sciences investment firm, on the closing of its second fund, Fund II, which raised over $600 million, surpassing its $500 million target
- Fund II is SR One's second fund since its 2020 spinout from GlaxoSmithKline
- The fund's investor base includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds, and family offices
- The Kirkland team included several partners and associates.
Kirkland & Ellis advised SR One, a transatlantic life sciences investment firm, on the closing of its second fund (Fund II) at over $600 million, substantially exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline in 2020 to form a fully independent investment firm. The diverse investor base of existing and new limited partners includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds and family offices. Read SR One’s press release The Kirkland team was led by investment funds partners Jean Jeong, Brian Delaney, Katie St. Peters and Ted Ughetta and associates Sarah Nolan and Soo Young Hong and tax partner Steve Butler and associate Grant Newman.
Article Author
Jean Jeong, Brian Delaney, Katie St. Peters, Ted Ughetta, Sarah Nolan, Soo Young Hong, Steve Butler, Grant Newman
The Sponsor